Skip to Content
Top

BY Ron Gilmore

Scientists at MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.

Simply put, it’s all in their DNA. The discovery could open up new avenues for treating certain kinds of brain cancer.

DNA, the body’s essential storehouse for genetic information, can do marvelous things such as passing on hereditary...

brain tumor

BY Ron Gilmore

Patrick Hwu, M.D., chair of Melanoma Medical Oncology and Sarcoma Medical Oncology at MD Anderson Cancer Center, has been named division head...

BY Ron Gilmore

It was announced last month that MD Anderson Cancer Center would be awarded more than $22 million in research grants from the Cancer Prevention...

BY Laura Sussman

In a pivotal Phase III study led by researchers at MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

The global study, led by Steven I. Sherman, M.D., associate vice-provost for Clinical Research and chair of Endocrine Neoplasia and Hormonal Disorders is published in the New England Journal...

thyroid cancer

BY Scott Merville

Triathlete and marathoner Leslie Russell teaches reading to children with dyslexia in the Spring Branch Independent School District. It’s...

BY Scott Merrville

The first experimental drug to be produced by MD Anderson’s drug discovery and development institute will kill cancer cells in a new way —...

BY Ron Gilmore

Tumors require blood to emerge and spread. That is why MD Anderson Cancer Center scientists believe targeting blood vessel cells known as...

BY Ron Gilmore

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein...

BY MD Anderson staff

Fourteen current and former MD Anderson researchers were represented in 11 of the 50 most-cited Journal of Clinical Oncology (JCO) articles...

BY Bryan Tutt

Concurrent HIV and cancer present special challenges in the clinic, regardless of which disease is diagnosed first. The simultaneous treatment...

BY Ronda Wendler

John Mendelsohn, M.D., president of MD Anderson from 1996-2011, recently received the Texas State History Museum Foundation’s "History-Making...